4. Psoriasis and Comorbidities

5. Psoriasis and Cardiometabolic Comorbidities

6. Physician’s Global Assessment (PGA)

7. Calculation of PASI

8. Absolute PASI Values (Cutoffs: 5, 3, or 2) Might Provide a Better Benchmark

9. Dermatology Life Quality Index (DLQI)

10. Some Thoughts on Psoriasis Disease Severity/Therapy Assessment Tools

11. Concept of Psoriasis Management

12. Improving Magnitude of Response: QoL Is Maximized in Patients Who Achieve PASI 90-100 Response

13. Significance of When Psoriasis Develops

14. Five Key Components to CLCI

15. Interaction of Key Interpersonal Components That Make Patients More or Less Vulnerable to CLCI

16. Does a More Aggressive Intervention Improve Psoriasis Patient Satisfaction

17. Effects of Stigmatization

18. Mismatch Between Patient and Physician Perspectives on Psoriasis

20. Greater disease severity & younger age  greater psychosocial burden Online survey, n=1033

21. MAPP Survey Results: Patient vs Physician on Contributors to Psoriasis Severity

22. Qualitative Research: Patient and Physician Interviews

23. Divergence in Patients' vs Physicians' Perspectives May Result in Suboptimal Treatment

24. A Holistic Approach to Treating Psoriasis

25. Building Trust; Improving Physician/Patient Communication

26. Secukinumab Efficacy Data Over 2 Years Randomized Extension of ERASURE and FIXTURE

27. UNCOVER-3: Study Design With Long-Term Extension

28. UNCOVER-3: Ixekizumab PASI 75 Response Rates to Week 60 (NRI)